Oesophageal squamous cell carcinoma (OSCC) - first-line treatment

Active Ingredient: Serplulimab

Indication for Serplulimab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Serplulimab in combination with fluoropyrimidine- and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 with a CPS ≥5.

For this indication, competent medicine agencies globally authorize below treatments:

3.0 mg/kg every 2 weeks

For:

Dosage regimens

Intravenous, 3 milligrams serplulimab per kilogram of body weight, once every 2 weeks.

Detailed description

The recommended dose in both the induction and maintenance phases is 3.0 mg/kg bodyweight serplulimab every 2 weeks until disease progression or unacceptable toxicity. During the induction phase, cisplatin is administered on day 1 of each 2-week cycle for up to 8 cycles, and 5-fluorouracil on day 1 of each 2-week cycle for up to 12 cycles.

For use in combination, see the Summary of Product Characteristics (SmPC) for the concomitant therapies.

Dose delay or discontinuation

Dose escalation or reduction of serplulimab is not recommended. Dose withholding or discontinuation may be required based on individual safety and tolerability. Dose withholding for up to 12 weeks for tolerability is acceptable.

Elderly

No dose adjustment is needed for elderly patients (≥65 years).

Dosage considerations

When administered in combination with chemotherapy, serplulimab should be given first followed by chemotherapy on the same day. Use separate infusion bags for each infusion.

Serplulimab must not be administered as an intravenous push or bolus injection.

Active ingredient

Serplulimab

Serplulimab (HLX10) is a humanised monoclonal IgG4 antibody, which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion.

Read more about Serplulimab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.